thyroid cancer and glp-1 Increased screening may lead to higher risk after initiation Overscreening of patients on glucagon-like

Patients with T2DM, persons at risk for AD, had a significantly lower associated risk of AD after administered exenatide, liraglutide and dulaglutide ( Conclusion Increasing evidence suggests that anti-diabetes medicine, GLP-1R agonists, have multiple neuroprotective mechanisms in AD models, such as anti-inflammation, anti-oxidative stress, reducing A aggregation/deposition and tau protein hyperphosphorylation, reducing neuronal apoptosis and neurotoxicity, increasing cell proliferation and neurogenesis, increasing synaptic plasticity, and other beneficial effects

Step 4 is duration and workup status

With the stacks combined mechanism established, the next focus shifts to what happens at the fat tissue level

10.12659/MSM.931630 214 ZhangF

doi: 10.1038/s12276-023-01068-z 117 GeJYinXChenL

Oliver, S